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Multi-basic cleavage siteA recombinant live attenuated inﬂuenza virus ΔH5N1 vaccine with a modiﬁed hemagglutinin (HA) and
intact neuraminidase genes from A/Vietnam/1203/04 (H5N1) and six remaining genome segments from A/
Ann Arbor/6/60 (H2N2) cold-adapted (AA ca) virus was previously shown to be attenuated in chickens,
mice and ferrets. Evaluation of the recombinant H5N1 viruses in mice indicated that three independent
factors contributed to the attenuation of the ΔH5N1 vaccine: the attenuating mutations speciﬁed by the AA
ca loci had the greatest inﬂuence, followed by the deletion of the H5 HA multi-basic cleavage site (MBS), and
the constellation effects of the AA genes acting in concert with the H5N1 glycoproteins. Restoring the MBS in
the H5 HA of the vaccine virus improved its immunogenicity and efﬁcacy, likely as a consequence of
increased virus replication, indicating that removal of the MBS had a deleterious effect on the
immunogenicity and efﬁcacy of the ΔH5N1 vaccine in mice.
© 2009 Published by Elsevier Inc.Introduction
The last century witnessed the emergence of three inﬂuenza
pandemics that were associated with signiﬁcant morbidity and
mortality worldwide: the H1N1 “Spanish” inﬂuenza pandemic of
1918, the H2N2 Asian inﬂuenza pandemic of 1957, and the 1968L. Suguitan),
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lsevier Inc.H3N2 pandemic that was recognized in Hong Kong. The ﬁrst pandemic
of this century caused by a swine origin H1N1 virus is under way. The
transmission of highly pathogenic avian inﬂuenza (HPAI) H5N1 viruses
from birds to humans in Hong Kong in 1997 that resulted in serious
disease and fatalities (Subbarao et al., 1998; Yuen et al., 1998) alerted
public health ofﬁcials to the pandemic potential of HPAI H5N1 viruses
because they were a novel inﬂuenza subtype to which the human
population has little or no immunity. Different clades of HPAI H5N1
viruses are now endemic in various avian species (Chen et al., 2006),
particularly in Southeast Asia, favoring the chances of adaptation or
genetic reassortment with human inﬂuenza viruses that might lead to
the acquisition of the ability of the virus to be transmissible among
humans. Theuseof anti-viral drugs andvaccinationof target populations
are crucial components of intervention strategies to prevent or lessen
the deleterious impact of a pandemic (Luke and Subbarao, 2006).
The development of live attenuated inﬂuenza virus vaccines
(LAIV) against HPAI H5N1 viruses is one of the approaches under
evaluation as part of a pandemic preparedness plan that is based on
licensed technology for the production of seasonal inﬂuenza vaccines
in the United States. LAIV offers potential advantages over other
vaccines, notably the ability to mimic the natural route of infection
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1995) andmucosal immunity (Clements andMurphy, 1986).We have
previously generated a recombinant LAIV ΔH5N1 vaccine where the
H5 hemagglutinin (HA) and N1 neuraminidase (NA) genes were
derived from A/Vietnam/1203/2004 (H5N1) (H5N1 wt) while the
internal protein genes were from the master donor strain A/Ann
Arbor/6/60 (H2N2) cold-adapted (AA ca) vaccine virus that confer
the properties of temperature sensitivity (ts, poor growth at 39 °C),
cold-adaptation (ca, efﬁcient replication at 25 °C), and attenuation
(att, restricted replication in the respiratory tract of ferrets) (Suguitan
et al., 2006). Using site-directedmutagenesis, Jin et al. (2003)mapped
the loci in the AA ca virus that were responsible for the ts phenotype:
K391E, E581G, and A661T in the polymerase basic protein 1 (PB1),
N265S in PB2, and D34G in nucleoprotein (NP). The H5 HA gene in the
H5N1 LAIV was modiﬁed (ΔH5) to remove multiple basic amino acids
at the cleavage site (MBS), a known virulence motif for poultry. The
ΔH5N1/AA ca vaccine was shown to be safe and attenuated in
chickens, mice and ferrets; although a single dose of the ΔH5N1/AA
ca vaccine failed to elicit detectable levels of serum neutralizing or
hemagglutination inhibiting antibodies against homologous and
heterologous wild-type (wt) H5N1 viruses, immunized mice were
protected from lethal challenge with homologous and heterologous
wt H5N1 viruses (Suguitan et al., 2006). Two doses of the ΔH5N1/
AA ca vaccine elicited high titers of neutralizing antibodies in the
serum and completely protected mice and ferrets from pulmonary
viral replication and systemic dissemination of homologous and
heterologous wt H5N1 challenge viruses.
We sought to understand the molecular basis of attenuation of the
ΔH5N1/AA ca vaccine in animal models by delineating the contribu-
tions of themodiﬁcations to the H5 HA gene, the phenotypes speciﬁed
by the loci in the AA ca internal protein genes, and the inﬂuence of the
AA genes in the context of H5N1 glycoproteins to the attenuation
phenotype in chickens and mice. In addition, we evaluated the
inﬂuence of the removal of the MBS on the immunogenicity and
efﬁcacy of the ΔH5N1/AA ca vaccine in mice.
Results
The in vitro phenotypes of the recombinant viruses
Three genetic modiﬁcations were applied to the H5N1 wt virus to
generate the ΔH5N1/AA ca vaccine virus, each of which could
contribute to its attenuation: (1) the MBS in the H5 HA gene was
removed (Fig. 1); (2) the avian H5N1 surface glycoprotein genes were
made to function in the backbone of the human AA inﬂuenza virus
genes; and (3) the set of mutations speciﬁed by the AA ca loci that
confers the ts, ca and att phenotypes were introduced (K391E, E581G,
and A661T in PB1, N265S in PB2, and D34G in NP). To assess the
relative contributions of each of these genetic components to the
attenuation of the ΔH5N1/AA ca vaccine virus in mice, several
recombinant viruses were generated (Fig. 2) and compared for their
level of replication in vitro and in vivo.Fig. 1. Deletion of multiple basic amino acids in the cleavage site of the H5 HA. The
nucleotide codon sequence, as well as the corresponding amino acids, around the H5
HA cleavage site of inﬂuenza A/Vietnam/1203/2004 (H5N1) wt virus are shown. In
addition to the deletion of several basic amino acids around the cleavage site of the H5
HA of the ΔH5N1wt virus (indicated by dashes), some residues were also mutagenized,
preserving the amino acid sequence (underscored). An arrow indicates the site of
cleavage of the HA into HA1 and HA2 subunits.A comparison of the titers of the recombinant viruses at 25 °C and
33 °C in primary chick kidney (PCK) cells revealed that all the viruses
tested were ca as they were able to replicate equally well at 25 °C as
they did at 33 °C, with less than 100-fold difference between the
respective titers at these temperatures for each virus (Table 1). These
ﬁndings are in agreement with our previous observations that several
wt human inﬂuenza viruses can replicate efﬁciently at 25 °C and that
the ca phenotype is not a discriminating phenotype among all
recombinant viruses (Suguitan et al., 2006). On the other hand, only
the recombinant viruses possessing the AA ca genetic background
were ts (Table 1), which was expected because this phenotype is
speciﬁed by loci in the internal protein genes of the AA ca virus
(Maassab and DeBorde, 1985; Jin et al., 2003; Jin et al., 2004). Viruses
with an intact H5 HA replicated to higher titers (≥100-fold) at 33 °C
compared to their ΔH5 HA virus counterparts (Table 1).
As expected, the recombinant viruses without the MBS in the H5
HA required trypsin to plaque efﬁciently in chick embryo ﬁbroblast
(CEF) cells (Bosch et al., 1981; Webster and Rott, 1987), in contrast to
the efﬁcient plaquing in the absence of trypsin displayed by
recombinant viruses that had the intact H5 HA (Table 1).
The role of MBS in the attenuation of an H5N1 LAIV
To determine the contribution of the removal of the MBS to the
attenuation of the ΔH5N1/AA ca vaccine virus, the pathogenicity of
recombinant viruses that contained the H5 HA with or without the
MBS on different genetic backgrounds was evaluated in mice and
chickens. Simply removing the MBS from the H5 HA of the H5N1 wt
virus rendered it non-lethal in mice and chickens (Table 2, H5N1 wt
vs ΔH5N1 wt), indicating that the MBS is indeed a major virulence
factor for mice and poultry, consistent with previous reports with
other H5 viruses (Bosch et al., 1979; Kawaoka and Webster, 1988;
Hatta et al., 2001). ΔH5N1 wt-infected chickens had detectable levels
of inﬂuenza-speciﬁc antibodies on day 14 post-infection (p.i.),
indicating that this recombinant virus replicated in the animals.
Oropharyngeal swabs from all chickens infected with the ΔH5N1 wt
virus and cloacal swabs from 5 out of 8 of these chickens tested
positive for virus shedding, with signiﬁcantly lower (N104–fold)
mean virus titers compared to the titers shed by chickens infected
with the H5N1wt virus (Table 2). Restoring theMBS in theΔH5N1/AA
ca vaccine made the virus (H5N1/AA ca) lethal to mice at a high dose
but remained non-lethal to chickens (Table 2) either because the AA ca
virus conferred the ts phenotype that restricted the level of replication
of the virus at the high body temperature of chickens or because
human inﬂuenza viruses are restricted in replication in chickens for
other reasons. The H5N1/AA wt virus was virulent in mice but only 1
out of 8 chickens inoculated with this virus intravenously (i.v.) died.
However, most of the birds developed mild to severe hemorrhage of
the combs and shanks from which they eventually recovered. In
contrast, theΔH5N1/AAwt virus was lethal tomice only at a very high
dose; although 1 out of 8 chickens infected i.v. with this virus died
(Table 2), hemorrhage of the combs and/or shanks were not observed
among the surviving chickens. No detectable virus shedding was
observed in the oropharynx and cloaca of chickens infectedwith either
H5N1/AA ca or H5N1/AA wt virus (Table 2).
The level of replication of the recombinant viruses was assessed in
different organs of mice. All the recombinant viruses that possess the
unmodiﬁed H5 HA (H5N1 wt, H5N1/AA wt and H5N1/AA ca)
replicated to signiﬁcantly higher titers in both the upper and lower
respiratory tract of mice compared to their respective virus counter-
parts that lacked the MBS (ΔH5N1 wt, ΔH5N1/AA wt and ΔH5N1/AA
ca, respectively) (Tables 3 and 4A). These results suggest that removal
of the MBS in the H5 HA is independently associated with a signiﬁcant
reduction in the level of viral replication in the respiratory tract of
mice. However, only the H5N1wt virus consistently disseminated and
replicated in the brain (Table 3), indicating that in the context of the
Fig. 2. Recombinant and wild-type inﬂuenza viruses used in this study. Colored bars indicate the origin of the inﬂuenza gene segment: A/Vietnam/1203/2004 (H5N1, red), A/Ann
Arbor/6/60 cold-adapted virus (AA ca, yellow) and A/Ann Arbor/6/60 wild-type virus (AA wt, blue). An “●” symbol denotes that multiple basic amino acids around the H5 HA
cleavage site were deleted. Asterisks indicate AA ca gene segments that contain loci that confer the ts phenotype.
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pulmonary dissemination.
The inﬂuence of avian H5N1 glycoproteins presented in the context of a
human (AA wt) inﬂuenza virus
When the six internal protein gene segments of the H5N1wt virus
were replaced with those of the AA wt virus, the recombinant H5N1/
AA wt virus remained highly lethal for mice but its virulence in
chickens was reduced (Table 2). Given that the AAwt virus is a human
inﬂuenza virus, the AA wt internal proteins might not be optimal for
the efﬁcient replication of the H5N1/AA wt virus in chickens. Despitethe virulence of H5N1/AAwt virus formice, however, the virus did not
disseminate to the brain (Table 3), suggesting that extrapulmonary
virus dissemination requires a highly cleavable H5 HA on an
appropriate genetic background. The ΔH5N1/AAwt virus was slightly
more virulent for mice than the nonlethal ΔH5N1 wt virus (Table 2).
Both the H5N1wt and H5N1/AAwt replicated to comparable levels in
the lungs of mice, as did the ΔH5N1 wt and ΔH5N1/AA wt virus pair
(Tables 3 and 4B). However, the titers of both H5N1wt and ΔH5N1wt
viruses in the upper respiratory tract of mice were signiﬁcantly higher
than their H5N1/AAwt andΔH5N1/AAwt virus counterparts on day 4
p.i. (Tables 3 and 4B). The ΔH5N1 wt virus was more infectious for
chickens than the ΔH5N1/AA wt, as evidenced by the antibody
Table 1
Evaluation of the ts phenotype and the dependence on trypsin for plaque formation of recombinant inﬂuenza viruses.
Virus Mean virus titer±standard errora (log10 TCID50/ml) tsb cac Requires trypsin to plaque on
chick embryo ﬁbroblast cells
25 °C 33 °C 39 °C
H5N1 wt 9.3±0.3 9.2±0.2 9.6±0.1 − + −
ΔH5N1 wt NDd ND ND ND ND +
H5N1/AA wt 8.9±0.4 9.0±0.1 8.9±0.1 − + −
ΔH5N1/AA wt 6.3±0.3 6.3±0.1 5.9±0.3 − + +
H5N1/AA ca 9.3±0.3 9.1±0.1 5.5±0.1 + + −
ΔH5N1/AA ca 6.7±0.2 7.0±0.1 5.0±0.1 + + +
AA wt 7.7±0.2 7.8±0.4 7.7±0.2 − + +
AA ca 8.0±0.6 7.8±0.1 5.3±0.1 + + +
a Data represent the average and standard error from 3 replicates in primary chick kidney cells.
b The ts phenotype was determined by virus titration in primary chick kidney cells at 33 °C and 39 °C. A virus is considered tswhen the difference in the mean titer of the virus at
33 °C and 39 °C is 100-fold or more.
c The ca phenotype was determined by virus titration in primary chick kidney cells at 25 °C and 33 °C. A virus is considered cawhen the difference in the mean titer of the virus at
25 °C and 33 °C is less than 100-fold.
d ND—not determined.
283A.L. Suguitan Jr. et al. / Virology 395 (2009) 280–288response; however 1 of 8 chickens inoculated with the ΔH5N1/AA wt
died (Table 2). These results suggest that the inﬂuence of the H5 HA
MBS on attenuation is also dependent on gene constellation and
recombinant ΔH5 viruses in which the internal protein genes were
derived from the H5N1 wt virus replicated more efﬁciently than
viruses in which the internal protein genes were derived from the AA
wt virus. The H5N1 surface glycoproteins are pathogenic in mice and
chickens when they are presented in an avian inﬂuenza virus
background (H5N1 wt), and are lethal in mice when presented in a
human inﬂuenza virus background (H5N1/AA wt).
The contribution of mutations in the internal protein genes of the AA
ca virus
To evaluate the contribution of the mutations in the AA ca internal
protein genes to the attenuation of the ΔH5N1/AA ca vaccine virus,
the virulence in mice and chickens of recombinant viruses on the AA
ca genetic background were compared to that of corresponding
viruses on the AA wt virus background. The recombinant viruses with
the AA ca internal protein genes were generally non-lethal to miceTable 2
Virulence of recombinant inﬂuenza viruses in mice and chickens.
Virus LD50 in micea
(log10 TCID50)
Pathogenicity in
Mortality
(dead/total)
Antibody
(detected/total)
i.v.b i.n.c i.v. i.n.
H5N1 wt 0.4 8/8 8/8 NAd NA
ΔH5N1 wt N6.5e 0/8 0/8 8/8 8/8
H5N1/AA wt 1.5 1/8f 0/8f 7/7 6/8
ΔH5N1/AA wt 5.5 1/8 0/8 0/7 0/8
H5N1/AA ca 5.5 0/8 0/8 1/8 0/8
ΔH5N1/AA cag N6.5 0/8 0/8 0/8 0/8
AA wt 4.8 NDh ND ND ND
AA cai N6.5 0/8 0/8 5/8 0/8
a Fifty percent mouse lethal dose (LD50) expressed as log10 TCID50 of virus. Groups of 5 fe
virus that resulted in 50% lethality was calculated by the Reed and Muench (1938) method
b Groups of eight 4-week-oldWhite Plymouth Rock chickens were inoculated i.v. with a do
and mortality up to 10 days p.i.
c A separate group of chickens were inoculated i.n. with 106 TCID50 of the reassortant vir
d NA—not applicable; all chickens infected with H5N1 wt were dead by day 2 p.i.
e An endpoint titer was not achieved.
f 6/8 (i.n.) and 6/8 (i.v.) birds developed mild to severe hemorrhage of comb and/or sh
g Data adapted from Suguitan et al. (2006).
h ND—not determined.
i Data adapted from Chen et al. (2003).and chickens while recombinant viruses on the AA wt genetic
background displayed varying degrees of lethality (Table 2). The AA
wt and ΔH5N1/AA wt viruses were rendered non-lethal in mice by
the introduction of the mutations associated with the ts and att
phenotypes of the AA ca virus, while the lethality of the H5N1/AA wt
virus was reduced by 10,000-fold on the AA ca background (Table 2).
As discussed previously, viruses on the AA ca genetic background
were restricted in replication in chickens either because the core body
temperature of 40 °C restricted the replication of the ts viruses or
because human inﬂuenza viruses replicate poorly in chickens. The
restricted replication of these viruses explains the absence of
detectable anti-inﬂuenza antibodies in chickens on day 14 p.i.
(Table 2). Intriguingly, inﬂuenza-speciﬁc antibodies were not
detected in any of the chickens inoculated intranasally (i.n.) or i.v.
with the ΔH5N1/AAwt virus either, suggesting that this recombinant
virus also grows poorly in chickens.
The level of replication of the recombinant viruses in different
mouse organs was also compared. With one exception (day 4 p.i.
H5N1/AA wt vs H5N1/AA ca), recombinant viruses on the AA ca
genetic background replicated to signiﬁcantly lower titers in thechickens following virus administered by indicated route
Virus Isolation and Titer in
Oropharynx Cloaca
Number of
shedding/total
Mean titer
(log10 EID50)
Number of
shedding/total
Mean Titer
(log10 EID50)
i.n. inoculation
8/8 7.1 8/8 6.2
8/8 2.6 5/8 1.5
0/8 ≤0.9 0/8 ≤0.9
0/8 ≤0.9 0/8 ≤0.9
0/8 ≤0.9 0/8 ≤0.9
0/8 ≤0.9 0/8 ≤0.9
ND ND ND ND
0/8 ≤0.9 0/8 ≤0.9
male BALB/c mice were infected with serial ten-fold dilutions of virus and the dose of
.
se of 0.2 ml of a 1:10 dilution of stock virus. The chickens were monitored for morbidity
uses to evaluate their infectivity through a simulated natural route of infection.
anks but eventually recovered.
Table 3
Level of virus replication in nasal turbinates, lungs, and brain of mice.
Virus Mean virus titer (log10 TCID50/g) in indicated tissuea
Nasal turbinates Lungs Brain
Day 2 p.i. Day 4 p.i. Day 2 p.i. Day 4 p.i. Day 2 p.i. Day 4 p.i.
H5N1 wt 4.5±0.2 6.5±0.3 8.1±0.2 8.1±0.1 1.9±0.2 5.4±0.3
ΔH5N1 wt 3.5±0.1 5.2±0.2 7.3±0.3 7.1±0.1 ≤1.5±0 ≤1.5±0
H5N1/AA wt 6.1±0.2 5.1±0.4 8.2±0.4 7.9±0.2 ≤1.5±0 ≤1.5±0
ΔH5N1/AA wt 3.7±0.4 3.6±0.1 6.8±0.3 6.9±0.2 ≤1.5±0 1.6±0.1
H5N1/AA ca 4.1±0.2 5.4±0.3 5.1±0.4 5.1±0.2 ≤1.5±0 ≤1.5±0
ΔH5N1/AA ca 2.0±0.3 2.6±0.1 3.6±0.1 2.8±0.3 ≤1.5±0 ≤1.5±0
AA wt 6.5±0.2 5.8±0.1 8.0±0.2 7.5±0.2 ≤1.5±0 ≤1.5±0
AA ca 4.3±0.4 4.2±0.2 3.8±0.2 5.6±0.5 ≤1.5±0 ≤1.5±0
a Groups of 8 female BALB/c mice were infected i.n. with 106 TCID50 of the indicated
virus. Four mice were euthanized on day 2 p.i. and four were euthanized on day 4 p.i.
Organs were harvested, homogenized and titered on MDCK cells. The limit of detection
for the assay was 101.5 TCID50/g.
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wt background (Tables 3 and 4C). However, the difference in viral
replicationwasmore pronounced in the lower respiratory tract where
viruses with the AA ca internal protein genes generally replicated to
about 100- to 1000-fold lower titer than viruses possessing the AA wt
internal protein genes (Table 4C). These ﬁndings are consistent with
the ts phenotype displayed by viruses on the AA ca genetic
background, where viral replication occurs in the cooler region of
the nasal passages but is restricted at the core body temperature of the
lungs. Thus, the mutations in the AA ca internal protein genes
contribute to the attenuation of the ΔH5N1/AA ca vaccine by
restricting viral replication in the respiratory tract of mice.
In summary, the additive effects of the genetic modiﬁcations
engineered into the H5N1 wt virus to generate the ΔH5N1/AA ca
vaccine contributed to the attenuation displayed by the ΔH5N1/AA ca
vaccine in mice (105.3 TCID50/g reduction in virus titers in the lungs
on day 4 p.i.; H5N1 wt vs ΔH5N1/AA ca). The attenuating mutations
in the AA ca internal protein gene segments exerted the greatest
inﬂuence on attenuation (104.1 TCID50/g reduction in pulmonary virus
titers, ΔH5N1/AA wt vs ΔH5N1/AA ca, Table 4C), followed by the
removal of the MBS in the H5 HA (101.0 TCID50/g reduction in
pulmonary virus titers, H5N1 wt vs ΔH5N1 wt, Table 4A) and with a
minor contribution from gene constellation effects (100.2 TCID50/g
reduction in pulmonary virus titers, ΔH5N1 wt vs ΔH5N1/AA wt,
Table 4B).Table 4
Genetic determinants of attenuation of LAIV H5N1 vaccine in mice.
Viruses compared to deﬁne role of: Reduction of replication between indicated
viruses in the respiratory tract
(log10 TCID50/g)
Nasal Turbinates Lungs
Reductiona p valueb Reduction p value
A. H5 HA MBS in replication
H5N1 wt vs ΔH5N1 wt 1.3 0.02 1.0 0.02
H5N1/AA wt vs ΔH5N1/AA wt 1.5 0.03 1.0 0.02
H5N1/AA ca vs ΔH5N1/AA ca 2.8 0.02 2.3 0.02
B. Mixing H5N1 and AA wt genes in replication
H5N1 wt vs H5N1/AA wt 1.4 0.03 0.2 0.20
ΔH5N1 wt vs ΔH5N1/AA wt 1.6 0.02 0.2 0.19
C. AA ca genes in replication
AA wt vs AA ca 1.6 0.02 1.9 0.02
H5N1/AA wt vs H5N1/AA ca +0.3c 0.77 2.8 0.02
ΔH5N1/AA wt vs ΔH5N1/AA ca 1.0 0.02 4.1 0.02
a Reduction in virus titer on the indicated tissue on day 4 p.i.
b Mann–Whitney U test; pb0.05 is considered statistically signiﬁcant.
c The virus titer of H5N1/AA ca is greater than H5N1/AA wt in the nasal turbinates.The inﬂuence of MBS on the immunogenicity and efﬁcacy of the
ΔH5N1/AA ca vaccine
Because a signiﬁcant contribution of the H5 HA MBS to the
attenuation of the ΔH5N1/AA ca vaccine was observed, the inﬂuence
of MBS on immunogenicity and efﬁcacy was further examined. Mice
that received a single dose of the vaccine i.n. were serially bled once a
week for 8 weeks and serum neutralizing antibody titers were
measured. Although neither the H5N1/AA ca nor the ΔH5N1/AA ca
viruses elicited appreciable serum neutralizing antibody titers until
day 28 post-vaccination (p.v.), the H5N1/AA ca virus was more
immunogenic than the ΔH5N1/AA ca vaccine from that time point
onward (Fig. 3). To evaluate the efﬁcacy of a single dose of vaccine,
immunized mice were challenged with 105 TCID50 of the H5N1 wt
virus on day 56 p.v. and viral titer was determined in the lungs on days
2 and 4 following challenge. A single dose of neither theΔH5N1/AA ca
nor H5N1/AA ca vaccine was able to completely protect mice from
pulmonary viral replication of the H5N1 wt virus (Fig. 4A). Although
mice immunized with a single dose of the ΔH5N1/AA ca vaccine had
signiﬁcantly lower pulmonary virus titers than unimmunized mice,
the titers remained high on days 2 (107.4/g) and 4 (105.8/g) p.i. In
contrast, mice that received a single dose of the H5N1/AA ca vaccine
were better protected from pulmonary viral replication of the H5N1
wt virus than mice that received the ΔH5N1/AA ca vaccine, with
lower virus titers on days 2 (106.1/g) and 4 (103.0/g) p.i. (Fig. 4A). The
level of replication of the challenge virus in H5N1/AA ca-immunized
mice was signiﬁcantly lower than that seen in ΔH5N1/AA ca-
immunized mice (pb0.05). Moreover, mice immunized with a single
dose of the H5N1/AA ca virus had no detectable shedding of the H5N1
wt challenge virus in the upper respiratory tract on day 4 p.i. (data not
shown). Two doses of either ΔH5N1/AA ca or H5N1/AA ca virus
administered 4 weeks apart completely protected mice from
pulmonary viral replication (Fig. 4B). A second dose of ΔH5N1/AA
ca or H5N1/AA ca virus vaccine boosted serum neutralizing antibody
titers, and comparable titers were achieved in mice immunized with
either virus 4 weeks after the administration of the second dose (data
not shown). These ﬁndings suggest that removal of the H5 HA MBS
signiﬁcantly restricted the replication of the vaccine virus in mice andFig. 3. Inﬂuence of the H5 HAMBS on the immunogenicity of the ΔH5N1/AA ca vaccine
virus. Groups of 8 female BALB/c mice were immunized i.n. with 105 TCID50 of either
ΔH5N1/AA ca or H5N1/AA ca virus. Serum samples were collected weekly and tested
in a neutralization assay against the H5N1 wt virus. Data represent geometric mean
neutralizing antibody titers for each group. The limit of detection for the assay is
indicated by the dashed line.
Fig. 4. Inﬂuence of the H5 HAMBS on the efﬁcacy ofΔH5N1/AA ca LAIV vaccine. Groups
of eight female BALB/c mice were immunized i.n. with a single dose of 105 TCID50 of
either ΔH5N1/AA ca or H5N1/AA ca virus (A) or two doses of the viruses 4 weeks apart
(B). Mice were challenged on day 56 p.v. with 105 TCID50 of H5N1 wt virus. Lungs were
harvested on days 2 and 4 following challenge. ⁎pb0.05 by Mann–Whitney U test,
compared to the mock-immunized group.
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efﬁcacy of the ΔH5N1/AA ca LAIV, but this effect was overcome by
administration of two doses of the vaccine virus.
Discussion
More than a decade after highly pathogenic H5N1 avian inﬂuenza
virus infections were identiﬁed in humans, we cannot predict
whether an H5N1 inﬂuenza pandemic will occur. HPAI H5N1 viruses
are now endemic in poultry in several countries and vaccination is the
most effective strategy to protect from an inﬂuenza pandemic.
Therefore, the development of safe and efﬁcacious vaccines against
HPAI H5N1 viruses remains a public health priority.
Ideally, an LAIV should replicate in the host to elicit cellular and
humoral immune responses without causing disease and a balance
between attenuation and immunogenicity must be achieved. We
developed an H5N1 LAIV vaccine using the technology employed to
manufacture the licensed seasonal LAIV vaccine that relies on the ts and
att phenotypes speciﬁed by the ﬁve loci in the three internal protein
gene segments of the AA ca master donor virus to ensure that the
vaccine virus replicates in the cooler upper respiratory tract and is
restricted in replication at the warmer temperature of the lungs. Theinternal protein gene segments of the AA ca virus imparted the ts and
att phenotypes to the ΔH5N1/AA ca vaccine virus mainly by restricting
viral replication in the lower respiratory tract. The ΔH5N1/AA ca
vaccine virus was not robustly immunogenic in mice and ferrets,
eliciting barely detectable neutralizing antibody titers 4 weeks after the
i.n. administration of a single dose of vaccine (Suguitan et al., 2006).
Although the pathogenicity of avian inﬂuenza viruses is polygenic
(Rott et al., 1979; Scholtissek et al., 1979), virulence in poultry is
mainly inﬂuenced by the cleavability of the HA protein (Bosch et al.,
1979). The HA is synthesized as a precursor protein andmust undergo
post-translational cleavage into two subunits for the virus to be
infectious (Lazarowitz and Choppin, 1975). HPAI H5 and H7 viruses
can possess an MBS in their HA, a structural feature that renders the
molecule cleavable by ubiquitous proteases such as furins (Stieneke-
Gröber et al., 1992), expanding the virus' tissue range and enabling
systemic spread. Results from our study conﬁrm that the H5 HA MBS
is a major virulence factor; removal of the MBS rendered the highly
virulent H5N1wt virus nonlethal in mice and chickens and altered the
virus' ability to replicate in extrapulmonary sites in mice. Like other
H5N1 vaccines that are currently in development, the MBS of the H5
HA had to be removed in the LAIV vaccine virus primarily to reduce
the potential threat to poultry and presumably to make the vaccine
safer for human use. In the case of the ΔH5N1/AA ca vaccine, the ts
phenotype and genes derived from a human inﬂuenza virus restrict its
replication in chickens. One consequence of the removal of the H5 HA
MBS in the ΔH5N1/AA ca vaccine is the attenuation of the vaccine
virus, decreasing the level of replication in the upper and lower
respiratory tract by about 100-fold compared to the H5N1/AA ca
virus. This low level of replication led to a reduction in viral load
associated with diminished immunogenicity and efﬁcacy following a
single dose of the ΔH5N1/AA ca vaccine compared to the H5N1/AA ca
virus in mice. The higher neutralizing antibody titers elicited by a
single dose of the H5N1/AA ca virus correlated with improved
efﬁcacy in protecting mice from pulmonary replication of the wt
challenge virus. A live attenuated avian paramyxovirus-vectored
vaccine for chickens expressing inﬂuenza H7 HA revealed a similar
dependency on the presence of an MBS and cleavability of the F
protein for efﬁcient replication and optimal protective efﬁcacy
(Swayne et al., 2003; Park et al., 2006). Although two doses of either
vaccine virus completely protected mice from pulmonary replication
of the wt challenge virus, a more immunogenic H5N1 vaccine would
be preferable during a pandemic when it may be difﬁcult to
administer 2 doses of vaccine and when dose-sparing will likely be
needed. The inﬂuence of genetic modiﬁcations introduced into the
H5N1 vaccine on cellular immune responses is not known; however,
passive transfer of sera from ΔH5N1 ca-immunized mice with
undetectable neutralizing antibodies protected naïve mice from lethal
challenge with the H5N1 wt virus, indicating that antibodies and/or
serum factors are sufﬁcient to mediate protection against lethality in
immunizedmice and that humoral immunity plays amajor role in this
protective immune response.
Little is known about the effect of removing the H5 HAMBS on the
stability of the H5HA protein, on the oligomerization of the H5HA and
its inﬂuence on vaccine immunogenicity. Wei et al. (2008) recently
reported that different recombinant H5 HA proteins vary in their
ability to elicit neutralizing antibodies depending on their multimeric
nature; high-molecular weight oligomers stimulated the strongest
antibody response, followed by the trimeric form of the H5 HA
molecule, while H5 HA monomers were poorly immunogenic. The
H5N1/AA ca andΔH5N1/AA ca vaccines likely express subtly different
H5 HA molecules on their viral surface and it is possible that these
nuances could inﬂuence the nature of the antibodies that they elicit.
The results presented in this study also revealed some interesting
ﬁndings regarding the inﬂuence of gene constellation effects, which
may include host-range restriction, on the phenotypic characteristics
of recombinant human-avian inﬂuenza viruses. Substitution of the AA
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rendered the H5N1/AA wt virus highly lethal in mice but not in
chickens, despite the presence of the MBS in the H5 HA. The lethality
of the H5N1/AA wt virus in mice was not associated with dissemina-
tion of the virus to the brain. These ﬁndings suggest that the
mammalian origin of the AA wt genetic background somehow
attenuates the H5N1/AA wt virus for chickens and that a highly
cleavable H5 HA requires an appropriate genetic background to
disseminate to extrapulmonary sites. A study conducted by Stech and
colleagues (2009) determined that even when a non-H5/H7
avirulent avian inﬂuenza virus strain acquires a polybasic cleavage
site in its HA, it is not enough to render the virus highly pathogenic,
indicating that determinants speciﬁed by other viral proteins or even
in other regions of the HA molecule itself can have a substantial
impact on its virulence. Salomon and colleagues (2006) earlier noted
that avian inﬂuenza viruses with a cleavable HA requires adaptive
changes in the polymerase genes to overcome the species barrier and
acquire virulence in mammals. This point is exempliﬁed by the
inﬂuenza A/Hong Kong/486/97 (H5N1) virus which, although
possessing the MBS in its H5 HA, remained less pathogenic in mice
but becomes highly pathogenic when its PB2 gene is substituted with
a PB2 gene from a virulent H5N1 strain that bears an E627K mutation
(Hatta et al., 2001; Chen et al., 2007), a mutation that has been
previously implicated in the host-range restriction of inﬂuenza A
viruses (Subbarao et al., 1993). Although a complex interplay
between gene constellation effects, glycosylation patterns in the HA
and NA, and individual gene mutations ultimately determine an
inﬂuenza virus' virulence (Hulse et al., 2004; Chen et al., 2007), it is
also plausible that an optimal set of polymerase proteins enables the
virus to replicate efﬁciently in its host and spread more rapidly to
other organs as well. In studies of attenuation of various inﬂuenza A
H3N2 and A/Puerto Rico/8/34 (H1N1) (PR8) virus recombinants,
Florent (1980) determined that recombinant H3N2 viruses were
virulent when all three polymerase genes (PA, PB1 and PB2) were
derived from PR8, indicating that the resulting constellation endows
optimal biological activity that results in enhanced viral replication
and pathogenicity.
In summary, the removal of the MBS in the H5 HA and the
mutations speciﬁed by the internal protein gene segments of AA ca
make signiﬁcant contributions to the attenuation of the ΔH5N1/AA ca
vaccine in mice by restricting viral replication in the respiratory tract.
However, removal of the MBS in the H5 HA also had the unintended
consequence of decreasing the immunogenicity and efﬁcacy of the
ΔH5N1/AA ca vaccine virus, likely resulting from restricted replica-
tion. Alternative approaches to improve the immunogenicity of the
H5N1 LAIV vaccine could be considered, possibly including the use of
immunostimulatory components to enhance host-protective effector
responses. It would also be interesting to explore the feasibility of
transferring the ts genetic signature of the AA ca virus strain to the
H5N1 wt genetic background, as has been successfully done with PR8
(Jin et al., 2004) and an H9N2 virus (Song et al., 2007). An H5N1 LAIV
will only be used upon the recommendation and guidance of public
health authorities in the event of a declared H5N1 pandemic, with
conﬁrmed efﬁcient human-to-human transmission, or when a
pandemic is already underway in the United States. In such a scenario,
the use of an immunogenic and efﬁcacious LAIV vaccinewith an intact
MBS in its H5 HA may be worth considering if the beneﬁts far
outweigh the risks posed by potential genetic reassortment with a wt
H5N1 pandemic virus.
Materials and methods
Generation of recombinant viruses
The generation of reverse genetics-derived ΔH5N1/AA ca vaccine,
including the removal of the MBS in the H5 HA, has been describedpreviously (Suguitan et al., 2006). The plasmids encoding the genes of
the desired recombinant viruses were transfected into a co-culture of
293T and Madin Darby canine kidney (MDCK) cells by lipofection
(TransIT, Mirus Bio Corp., Madison,WI). Seed virus stocks were cloned
twice and ampliﬁed in speciﬁc pathogen free eggs. All eight gene
segments of the recombinant viruses were ampliﬁed by RT-PCR and
the sequences were conﬁrmed to be identical to the plasmids used in
transfection.
Phenotypic analyses of the reassortant viruses
The ca and ts phenotypes of the parent and reassortant viruses
were evaluated by comparing their growth and replication in PCK
cells (Charles River Laboratories, USA) at 25 °C and 33 °C (for ca
phenotype) and 33 °C and 39 °C (for ts phenotype). The cells that
were incubated at 25 °C were examined for cytopathic effect (CPE) on
day 10 p.i. while cells that were incubated at 33 °C and 39 °C were
examined for CPE on day 6 p.i. as previously described (Suguitan et al.,
2006). By convention, a virus was considered ca if the virus titer at
25 °C was within 100-fold of the titer at 33 °C and viruses that
displayed 100-fold or greater reduction in titers at 39 °C compared
with that exhibited at the permissive temperature of 33 °C were
considered ts (Suguitan et al., 2006).
Trypsin-dependence assay
CEF cells were seeded to a density of 5×106 cells/25 cm2 of a 6-
well tissue culture plate (Multiwell Primaria, Becton Dickinson,
Franklin Lakes, NJ) and incubated overnight to achieve conﬂuency.
CEF cells were then inoculated with 0.1 ml of serially-diluted virus in
L-15 medium (Invitrogen, Grand Island, NY). The virus was adsorbed
to cells for 1 h at room temperature. The inocula were removed and
the cells were overlaid with 1.8% agar (Difco, BD Diagnostic Systems,
Palo Alto, CA) supplemented with 2×Medium 199 (Sigma, St. Louis,
MO), 2×antibiotics/antimycotic (Invitrogen, Grand Island, NY), with
or without 0.5 μg/ml of TPCK trypsin (Sigma, St. Louis, MO).
Recombinant viruses on the AA ca genetic backgroundwere incubated
at 33 °C for 5 days while viruses on the A/Vietnam/1203/04 or AAwt
genetic backgrounds were incubated at 37 °C for 3 days. The overlay
was carefully removed and the wells were stained with crystal violet
to visualize plaques.
Pathogenicity and infectivity study in chickens
The pathogenicity of the recombinant viruses was assessed
through a pathotyping test where the viruses were administered
i.v. to groups of eight 4-week-old White Plymouth Rock chickens
at a standard dose of 0.2 ml of a 1:10 dilution of stock virus. The
chickens were monitored for morbidity and mortality up to
10 days p.i. (USAHA, 1994). A separate group of chickens were
inoculated i.n. with 106 50% tissue culture infectious doses
(TCID50) of the recombinant viruses to evaluate their infectivity
through a more natural route of infection. Oropharyngeal and
cloacal swabs were collected for virus isolation on day 3 p.i. or on
the day of death for chickens that died before day 3 p.i. All
surviving chickens were euthanized and bled on day 14 p.i. and
their sera were tested for evidence of seroconversion by an agar
gel precipitin assay, the prescribed initial screening test for the
detection of inﬂuenza A-speciﬁc antibodies in chickens and turkeys
that is recommended by the USDA-National Veterinary Services
Laboratories, National Poultry Improvement Plan and World
Organization for Animal Health (OIE) (Swayne et al., 2008). The
assay detects antibodies 10–14 days following intranasal challenge
with low pathogenicity avian inﬂuenza viruses in chickens (Beck
et al., 2003). However, the limit of detection of antibodies by this
assay is not known.
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To determine the 50% lethal dose (LD50) of the different
recombinant viruses, groups of 6- to 8-week-old female BALB/c
mice were lightly anesthetized and infected i.n. with serial 10-fold
dilutions of the viruses in 50 μl. Mice were monitored daily until
day 14 p.i. for mortality and weight loss. Mice that lost N25% of
their initial body weight were euthanized in accordance with our
animal study protocol. The ability of the viruses to replicate in
different organs was also examined. Groups of 8 female BALB/c
mice were infected with 106 TCID50 of the recombinant viruses and
4 mice from each group were euthanized on days 2 and 4 p.i. Virus
titers in lungs, nasal turbinates, and brains were quantiﬁed as
previously described (Suguitan et al., 2006). Samples from mice
that were inoculated with recombinant viruses on the AA ca
genetic background were incubated at 33 °C for 7 days while
samples from mice that received viruses on the A/Vietnam/1203/
04 or AA wt genetic backgrounds were incubated at 37 °C for
4 days and the cells were examined for CPE. Viral titers were
expressed as log10 TCID50/g of tissue and were calculated by the
Reed and Muench method (1938). Log-transformed viral titers were
compared using the Mann–Whitney U test. A p valueb0.05 was
considered signiﬁcant.
The inﬂuence of MBS on the immunogenicity and efﬁcacy of an
H5N1 LAIV
Groups of lightly anesthetized female BALB/c mice were immu-
nized by i.n. instillation with 105 TCID50 of H5N1/AA ca and ΔH5N1/
AA ca in 0.05 mL of L15. Blood samples were collected weekly from
day 7 to day 56 p.v. The immunized and unimmunized age-matched
control mice were challenged on day 56 p.v by intranasal inoculation
with 105 TCID50 of the H5N1 wt virus in 0.05 mL of L15 given under
light anesthesia. Four mice from each group were euthanized on days
2 and 4 p.i. and lungs and nasal turbinates were harvested,
homogenized and titered on MDCK cells as described (Suguitan
et al., 2006). In a separate experiment, groups of female BALB/c mice
immunized with two doses of L15 medium (mock), 105 TCID50 of
H5N1/AA ca or 105 TCID50 of ΔH5N1/AA ca i.n. given 4 weeks apart
were challenged with 105 TCID50 of H5N1 wt virus on day 56 p.v. and
4 mice from each group were euthanized on days 2 and 4 p.i. and
lungs and nasal turbinates were harvested and titered on MDCK cells.
The MDCK cells were incubated at 37 °C for 4 days and the cells were
examined for CPE.
Serologic analyses
A microneutralization assay on MDCK cells was performed as
described previously (Suguitan et al., 2006). Brieﬂy, serial two-fold
dilutions of mouse sera were mixed with 100 TCID50 of the H5N1 wt
virus, incubated for 1 h at room temperature and then transferred in
quadruplicate to MDCK cell monolayers. Neutralizing antibody titer
was deﬁned as the reciprocal of the highest dilution of serum that
completely neutralized the infectivity of 100 TCID50 of thewt virus on
MDCK cells. Infectivity was identiﬁed by the presence of CPE after
4 days of incubation at 37 °C.
All experiments involving infectious wt H5N1 avian inﬂuenza
viruses were performed in BSL-3 containment laboratories approved
by the USDA and Centers for Disease Control and Prevention. Animal
experiments were approved by the National Institutes of Health
Animal Care and Use Committee.
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